Drugs / RO6885247
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02240355 | Nov 2014 → Jul 2015 | spinal muscular atrophy | Hoffmann-La Roche | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-02 | PTC Therapeutics | Results Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress ptcbio.com ↗
Data from Part 1 of the FIREFISH clinical trial demonstrated that after 16 months of treatment, 82% (14/17) of high-dose patients had a CHOP-INTEND score ≥40. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-10-02 | PTC Therapeutics | Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress ptcbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO6885247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02240355 ↗ |